ABS0080 THREE YEARS REAL WORLD PERSISTENCE DATA OF FRESENIUS KABI – ADALIMUMAB BIOSIMILAR (FK-ada), MSB11022, IN INFLAMMATORY ARTHRITIS (IA)
Notice bibliographique
Résumé
Background: Objectives: The objective of the analysis was to understand the long-term (36 months) persistence of FK- ada in inflammatory arthritis patients who had either a mandatory switch from Humira, or patients who switched from other adalimumab biosimilars, or biologic-naïve patients. Humira, and other adalimumab biosimilars switched to FK-ada were combined into one "adalimumab only" switch cohort presented here. Methods: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) enrolled in KabiCare and who received at least one dose of FK-adalimumab biosimilar, MSB 11022, were follow-up from Feb 2021 to Nov 21, 2024, in Canada. Medication initiation date and stop date, disease type and patient previous treatment were recorded in the database. The stop date was the date when KabiCare was informed that medication was discontinued. For Kaplan Meier estimators of persistence on treatment, patients continuing medication were censored at the maximal follow-up date, November 21, 2024. Log-rank tests were used to examine if there were differences in medication persistence/adherence among RA, PsA and AS, and between naïve group vs. switch group by disease. The analysis further explored if gender and age affected treatment persistence. Results: A total of 4324 AI patients were followed (2008 RA, 1344 AS and 972 AS). Combined IA patients at 36 months: 72% (95% CI [69%, 75%]) of patients that switched from Humira, or adalimumab biosimilar, to FK-ada persisted on FK-ada treatment; whereas 48% (95% CI [45%, 52%]) of biologic naïve patients persisted on FK-ada (Figure 1A). At 36 months for RA patients: >68 years old patients showed persistence estimate of 62% ([57%, 67%]) and was significantly higher vs. 18-42 years old patients with persistence of 42% ([32%, 52%]). 43-67 years old patient group had persistence rate estimate of 56% ([51%, 60%]). Age was not a significant factor impacting MSB11022 persistence for PsA or AS patients (Figure 2B-D). At 36 months, male PsA & AS patients showed higher persistence probability versus female PsA and AS patients (PsA: 69% vs 53% and AS: 69% vs 49%; P < 0.001). No difference for male and female persistence probability in RA patients were observed (Figure 3B-D). Conclusion: In general, Humira and adalimumab biosimilars to FK-ada switch showed high persistence probability at 36 months for the inflammatory arthritis diseases: RA/PsA/AS. Older aged was associated with a longer persistence probability in RA; whereas male gender for patients with PsA/AS was associated with a longer persistence probability for patients on FK-ada. REFERENCES: NIL . Acknowledgements: NIL . Disclosure of Interests: Don Truong Fresenius Kabi Employee, Pooneh Heidari Fresenius Kabi Canada, Joëlle Monnet Fresenius Kabi Switzerland. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,002 | 0,003 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,001 |
| Bibliométrie | 0,001 | 0,002 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,001 | 0,000 |
| Science ouverte | 0,001 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,001 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».